Denali Therapeutics Company Top Insiders
| DNLI Stock | USD 15.99 0.01 0.06% |
Denali Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Denali Therapeutics suggests that almost all insiders are panicking. Denali Therapeutics employs about 445 people. The company is managed by 25 executives with a total tenure of roughly 98 years, averaging almost 3.0 years of service per executive, having 17.8 employees per reported executive.
| Ryan Watts CEO President CEO, Co-Founder, Director |
| Marc TessierLavignec Chairman Chairman of the Board, Co-Founder |
Denali Therapeutics' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2024-04-15 | Vicki L Sato | Disposed 1666 @ 18.29 | View | ||
| 2024-04-01 | Steve E Krognes | Disposed 92500 @ 20.5 | View | ||
| 2024-02-15 | Vicki L Sato | Disposed 1666 @ 18.37 | View | ||
| 2024-02-13 | Steve E Krognes | Disposed 2750 @ 17.29 | View | ||
| 2024-01-16 | Vicki L Sato | Disposed 1666 @ 18.42 | View | ||
| 2024-01-10 | Carole Ho | Disposed 4668 @ 19.02 | View | ||
| 2024-01-09 | Ryan J Watts | Disposed 7818 @ 19.78 | View | ||
| 2024-01-05 | Ryan J Watts | Disposed 17483 @ 19.43 | View | ||
| 2023-12-15 | Vicki L Sato | Disposed 1666 @ 23.39 | View | ||
| 2023-11-15 | Vicki L Sato | Disposed 1666 @ 19.13 | View | ||
| 2023-10-16 | Vicki L Sato | Disposed 1666 @ 20.66 | View | ||
| 2023-09-15 | Vicki L Sato | Disposed 1666 @ 23.62 | View | ||
| 2023-08-23 | Carole Ho | Disposed 2522 @ 23.22 | View | ||
| 2023-08-21 | Ryan J Watts | Disposed 2309 @ 22.59 | View |
Monitoring Denali Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Denali |
Denali Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Denali Therapeutics' future performance. Based on our forecasts, it is anticipated that Denali will maintain a workforce of under 450 employees by May 2024.Denali Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.0941) % which means that it has lost $0.0941 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1401) %, meaning that it created substantial loss on money invested by shareholders. Denali Therapeutics' management efficiency ratios could be used to measure how well Denali Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.13. The current Return On Capital Employed is estimated to decrease to -0.19. As of now, Denali Therapeutics' Asset Turnover is decreasing as compared to previous years.The current Common Stock Shares Outstanding is estimated to decrease to about 86.7 M. The Denali Therapeutics' current Net Loss is estimated to increase to about (278.7 M)
Denali Therapeutics Workforce Comparison
Denali Therapeutics is rated below average in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 17,884. Denali Therapeutics holds roughly 445 in number of employees claiming about 2.49% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.44) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.6) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.6. Denali Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Denali Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Denali Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Denali Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-03-01 | 0.4118 | 7 | 17 | 837,840 | 187,491 |
| 2023-09-01 | 0.1053 | 2 | 19 | 12,526 | 64,730 |
| 2023-06-01 | 1.8571 | 26 | 14 | 263,650 | 186,564 |
| 2023-03-01 | 0.3571 | 10 | 28 | 742,920 | 201,843 |
| 2022-12-01 | 0.25 | 1 | 4 | 20,000 | 60,000 |
| 2022-09-01 | 0.25 | 3 | 12 | 107,500 | 181,656 |
| 2022-06-01 | 5.6667 | 17 | 3 | 233,465 | 60,000 |
| 2022-03-01 | 0.7647 | 13 | 17 | 719,352 | 139,903 |
| 2021-12-01 | 0.0323 | 1 | 31 | 100,000 | 452,938 |
| 2021-09-01 | 0.0303 | 1 | 33 | 9,045 | 114,936 |
| 2021-06-01 | 0.5778 | 26 | 45 | 182,801 | 898,272 |
| 2021-03-01 | 0.1429 | 16 | 112 | 639,650 | 3,290,321 |
| 2020-12-01 | 0.1333 | 2 | 15 | 52,906 | 633,847 |
| 2020-09-01 | 0.8889 | 8 | 9 | 102,572 | 1,471,681 |
| 2020-06-01 | 1.0667 | 16 | 15 | 147,488 | 2,867,855 |
| 2020-03-01 | 1.3 | 13 | 10 | 975,687 | 3,930,919 |
| 2019-12-01 | 0.1765 | 3 | 17 | 8,961 | 103,104 |
| 2019-09-01 | 0.2857 | 6 | 21 | 25,470 | 897,140 |
| 2019-06-01 | 0.3103 | 18 | 58 | 260,178 | 289,747 |
| 2019-03-01 | 0.3387 | 21 | 62 | 845,781 | 368,991 |
| 2018-12-01 | 0.3 | 6 | 20 | 104,322 | 209,278 |
| 2018-09-01 | 0.75 | 3 | 4 | 33,858 | 71,667 |
| 2018-06-01 | 7.0 | 7 | 1 | 172,898 | 5,918 |
| 2018-03-01 | 5.0 | 5 | 1 | 877,954 | 0.00 |
| 2017-12-01 | 0.9474 | 54 | 57 | 58,151,022 | 55,573,197 |
Denali Therapeutics Notable Stakeholders
A Denali Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Denali Therapeutics often face trade-offs trying to please all of them. Denali Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Denali Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Ryan Watts | President CEO, Co-Founder, Director | Profile | |
| Marc TessierLavignec | Chairman of the Board, Co-Founder | Profile | |
| Alexander Schuth | Co-Founder, COO, Head of Corporate Development | Profile | |
| Dana Andersen | CTO and Manufacturing Officer | Profile | |
| Peter Klein | Independent Director | Profile | |
| Douglas Cole | Independent Director | Profile | |
| Steve Krognes | Treasurer Director | Profile | |
| Jennifer Cook | Independent Director | Profile | |
| Vicki Sato | Independent Director | Profile | |
| David Schenkein | Independent Director | Profile | |
| Robert Nelsen | Independent Director | Profile | |
| Jay Flatley | Director | Profile | |
| Carole MD | Chief Development | Profile | |
| Tyler Nielsen | Senior Finance | Profile | |
| Cindy Dunkle | Chief Officer | Profile | |
| Joe Lewcock | Chief Officer | Profile | |
| Carole Ho | Chief Medical Officer | Profile | |
| Peter Chin | Senior Affairs | Profile | |
| Mark Rowen | Vice Development | Profile | |
| Chris Walsh | General Counsel | Profile | |
| Laura Hansen | Vice Relations | Profile | |
| Alexander MD | CFO, CoFounder | Profile | |
| Marc TessierLavigne | Chairman CoFounder | Profile | |
| Tony Estrada | Senior Sciences | Profile | |
| Katie Peng | Chief Officer | Profile |
About Denali Therapeutics Management Performance
The success or failure of an entity such as Denali Therapeutics often depends on how effective the management is. Denali Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Denali management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Denali management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.13) | (0.13) | |
| Return On Capital Employed | (0.18) | (0.19) | |
| Return On Assets | (0.13) | (0.13) | |
| Return On Equity | (0.14) | (0.15) |
The data published in Denali Therapeutics' official financial statements usually reflect Denali Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Denali Therapeutics. For example, before you start analyzing numbers published by Denali accountants, it's critical to develop an understanding of what Denali Therapeutics' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Denali Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Denali Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Denali Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Denali Therapeutics. Please utilize our Beneish M Score to check the likelihood of Denali Therapeutics' management manipulating its earnings.
Denali Therapeutics Workforce Analysis
Traditionally, organizations such as Denali Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Denali Therapeutics within its industry.Denali Therapeutics Manpower Efficiency
Return on Denali Therapeutics Manpower
| Revenue Per Employee | 742.8K | |
| Revenue Per Executive | 13.2M | |
| Net Loss Per Employee | 326.3K | |
| Net Loss Per Executive | 5.8M | |
| Working Capital Per Employee | 2.2M | |
| Working Capital Per Executive | 39.4M |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Denali Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for Denali Stock analysis
When running Denali Therapeutics' price analysis, check to measure Denali Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Denali Therapeutics is operating at the current time. Most of Denali Therapeutics' value examination focuses on studying past and present price action to predict the probability of Denali Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Denali Therapeutics' price. Additionally, you may evaluate how the addition of Denali Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |
Is Denali Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.06) | Revenue Per Share 2.406 | Quarterly Revenue Growth (1.00) | Return On Assets (0.09) | Return On Equity (0.14) |
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Denali Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.